Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie
Go back to Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie| AbbVie (NYSE: ABBV) | Delayed: 256.28 +2.98 (1.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $253.30 | 52 Week High | $68.12 | |||
| Open | $253.98 | 52 Week Low | $50.71 | |||
| Day High | $258.38 | P/E | 55.59 | |||
| Day Low | $253.10 | EPS | $4.61 | |||
| Volume | 2,001,130 | |||||
